Research programme: protease-activated prodrugs - Cangene
Alternative Names: TST 10138; TST 220; TST 304; TST 334; Tumour-activated prodrugs research programme - CangeneLatest Information Update: 16 Jul 2016
At a glance
- Originator Twinstrand Therapeutics
- Developer Emergent BioSolutions
- Class Plant proteins; Recombinant proteins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Prostate cancer; Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Viral-infections in Canada